Patents Examined by Shirley V. Gembeh
  • Patent number: 10112933
    Abstract: Embodiments of the invention include methods of treating, preventing, and/or reducing the risk of fibrosis in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction of the risk of fibrosis. In at least particular cases, the small molecules are inhibitors of STAT3.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: October 30, 2018
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: David J. Tweardy, Moses M. Kasembeli, Marvin X. Xu, Sandeep K. Agarwal, Mesias Pedroza
  • Patent number: 10105323
    Abstract: The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 23, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Roman Messerschmid, Peter Lach, Torsten Sokoliess, Peter Stopfer, Dirk Trommeshauser
  • Patent number: 10098888
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: October 16, 2018
    Assignee: Epizyme, Inc.
    Inventors: Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki
  • Patent number: 10093694
    Abstract: Described herein are compounds that inhibit or prevent protein aggregation, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with protein aggregation.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: October 9, 2018
    Assignees: GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGY CO, LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Rui Hou, Kang Zhang, Gen Li
  • Patent number: 10092531
    Abstract: Valproate is useful as an antifungal agent. The valproate compositions can be used to treat fungal infections. The valproate compositions can be formulated as topical antifungals.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: October 9, 2018
    Assignee: Wayne State University
    Inventors: Miriam L. Greenberg, Rania M. Deranieh
  • Patent number: 10085996
    Abstract: A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof and (b) a gonadorelin agonist and, optionally, (c) an antiestrogen agent, particularly for use in the treatment or prevention of a cancer; uses of such a combination in the preparation of a medicament for the treatment or prevention of a cancer; pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a cancer in a subject comprising administering to said subject a therapeutically effective amount of such a combination.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 2, 2018
    Inventors: Samit Hirawat, Cristian Massacesi
  • Patent number: 10085979
    Abstract: Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: October 2, 2018
    Assignee: IGNYTA, INC.
    Inventors: Zachary Dolph Hornby, Gang Li, David Wesley Anderson, Garrett M. Brodeur, Radhika Iyer
  • Patent number: 10081619
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 25, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
  • Patent number: 10080732
    Abstract: A method of stimulating ventilatory and/or respiratory drive in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a cystine ester or a pharmaceutically acceptable salt thereof. Embodiments described herein relate to compositions and methods of stimulating ventilatory and/or respiratory drive in a subject in need thereof, and particularly relates to compositions and methods of treating breathing diseases and/or disorders associated with impaired ventilatory and/or respiratory drive.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: September 25, 2018
    Assignee: Case Western Reserve University
    Inventors: Benjamin Gaston, Stephen Lewis
  • Patent number: 10076528
    Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: September 18, 2018
    Assignee: Pop Test Oncology Limited Liability Company
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Patent number: 10071070
    Abstract: A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial ?-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: September 11, 2018
    Assignee: Baylor Research Institute
    Inventor: Charles R. Roe
  • Patent number: 10071071
    Abstract: A method for influencing behavior in young, adult or aged pet animals which comprises systemically administering a behavior influencing quantity of an omega-3 fatty acid or mixture of omega-3 fatty acids.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: September 11, 2018
    Assignee: Colgate-Palmolive Company
    Inventors: Steven Curtis Zicker, Chadwick E. Dodd, Dennis Jewell, Dale A. Fritsch
  • Patent number: 10071160
    Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: September 11, 2018
    Assignees: The University of British Columbia, Centre for Drug Research and Development
    Inventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
  • Patent number: 10064809
    Abstract: A viscosity building composition is described. The viscosity building composition comprises a fatty alcohol in combination with one or more polyglyceryl esters. In one embodiment, the composition contains a fatty alcohol in combination with a polyglyceryl monoester. In an alternative embodiment, the composition contains a fatty alcohol combined with a polyglyceryl polyester, such as a polyglyceryl diester or a polyglyceryl triester. In still another embodiment, the composition comprises a fatty alcohol mixed with a blend of polyglyceryl esters. The blend may include at least one polyglyceryl monoester in combination with at least one polyglyceryl polyester, such as a diester, triester, tetraester or decaester. The polyglyceryl polyester is present generally in an amount greater than the monoester. In an alternative embodiment, the blend may include two or more polyglyceryl polyesters.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: September 4, 2018
    Assignee: Arch Personal Care Products, LP
    Inventors: Guojin Lu, Khat Kevin Lou, Joseph LiBrizzi, Mark Garrison
  • Patent number: 10066188
    Abstract: The present invention relates to the use of diesters of 2,5-dimethyl-2-hexenedioic acid, 2,5-dimethyl-3-hexenedioic acid and 2,5-dimethyladipic acid or a mixture thereof as a fragrance or as flavor, to a method for imparting or modifying a scent or a flavor to a composition by including said compounds into such composition, to a fragrance containing composition and/or a fragrance material containing said compounds and to a process for preparing diesters of 2,5-dimethyladipic acid.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 4, 2018
    Assignee: BASF SE
    Inventors: Nicolas Vautravers, Joaquim H. Teles, Nicolas Marion
  • Patent number: 10064874
    Abstract: The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-memopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reducing elasticity and/or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: September 4, 2018
    Assignee: HAVAH THERAPEUTICS PTY LTD.
    Inventor: Stephen Nigel Birrell
  • Patent number: 10058530
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: August 28, 2018
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • Patent number: 10058563
    Abstract: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: August 28, 2018
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Patent number: 10058539
    Abstract: This present invention relates to a method of treating a autoimmune, respiratory and/or inflammatory disease or condition (e.g., psoriasis, rheumatoid arthritis, asthma, COPD). The method comprises administering a PI3K Delta inhibitor or a dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor. The present invention also relates to pharmaceutical compositions containing a PI3K Delta or dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: August 28, 2018
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop K. Vakkalanka, Srikant Viswanadha
  • Patent number: 10052335
    Abstract: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17?-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: August 21, 2018
    Assignee: The Population Council, Inc.
    Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Roberta Brinton, Martine El-Etr, Abdelmouman Ghoumari, Rachida Guennoun